From weight-loss pills to cancer drugs, these healthcare giants are investing in pharmaceutical breakthroughs.

For the first time in 16 years, oncology is no longer the largest contributor to late-stage pipeline value, Deloitte has found. Pharma R&D returns for the world's top 20 pharma companies have improved ...

Indian pharma is entering its next growth phase as a new segment gains traction. We analyse four companies building this ...